News


  • 04 February 2014

    NovaMedica and Skolkovo Foundation Sign Agreement to Build R&D center

    NovaMedica and Skolkovo Foundation Sign Agreement to Build R&D center

    NovaMedica Innotech, R&D unit of NovaMedica, a Russian pharmaceutical resident company of the Skolkovo Innovation Center, and Skolkovo Foundation signed the agreement to collaborate in building R&D center on the territory of Skolkovo Technopark.

  • 03 February 2014

    Leading Breast Cancer Expert, George W. Sledge, Jr., M.D., Joins Syndax as an Independent Director

    Leading Breast Cancer Expert, George W. Sledge, Jr., M.D., Joins Syndax as an Independent Director

    Syndax Pharmaceuticals, Inc., today announced the appointment of distinguished breast cancer specialist, George W. Sledge, Jr., M.D., to its board of directors as an independent director. Dr. Sledge is currently professor and chief of medical oncology at Stanford University Medical Center.

  • 31 January 2014

    Regado Biosciences Announces $20 Million Private Placement

    Regado Biosciences Announces $20 Million Private Placement

    Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that it has entered into a definitive agreement to sell $20 million of its common stock in a private placement to new and existing investors. Under the agreement, the investors will purchase an aggregate of 4 million shares of common stock at a purchase price of $5.00 per share. 

  • 29 January 2014

    Regado Biosciences, Inc., Demonstrates Safety of Early Sheath Removal in Patients Treated with REG1 in Phase 2b Study

    Regado Biosciences, Inc., Demonstrates Safety of Early Sheath Removal in Patients Treated with REG1 in Phase 2b Study

    Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced the publication of additional findings from its completed Phase 2b RADAR trial in the Journal of Invasive Cardiologydemonstrating the safety of early sheath removal in patients treated with REG1.

  • 23 January 2014

    Syndax Announces Appointment of Richard P. Shea as Independent Director and Chair of the Audit Committee

    Syndax Announces Appointment of Richard P. Shea as Independent Director and Chair of the Audit Committee

    Syndax Pharmaceuticals, Inc. today announced the appointment of Richard P. Shea to its board of directors as an independent director and chairman of the audit committee. Mr. Shea is an experienced biotechnology executive with wide ranging experience in finance and operations as well as managing venture financings, initial public offerings, secondary offerings and mergers and acquisitions.

  • 13 January 2014

    Marinus Pharmaceuticals Bolsters Its Board of Directors and Executive Management

    Marinus Pharmaceuticals Bolsters Its Board of Directors and Executive Management

    Elects Two Life Sciences Veterans, Enrique J. Carrazana, M.D. and Jay P. Shepard, to Its Board of Directors; Appoints Edward F. Smith as Chief Financial Officer.

  • 19 December 2013

    Nuvo Research and NovaMedica sign agreement to market Pennsaid in Russia

    Nuvo Research and NovaMedica sign agreement to market Pennsaid in Russia

    Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company with a diverse portfolio of products in the areas of topical pain and immunology, and NovaMedica LLC (NovaMedica), a Russian pharmaceutical company, today announced that they have signed a supply and distribution agreement providing NovaMedica the exclusive rights to market and sell Nuvo’s Pennsaid 1.5% and Pennsaid 2% products in Russia and some of the Community of Independent States (CIS).  

  • 18 December 2013

    Regado Biosciences, Inc. Adds World-Class Interventional Cardiologist and Researcher to Medical Advisory Board

    Regado Biosciences, Inc. Adds World-Class Interventional Cardiologist and Researcher to Medical Advisory Board

    Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that Deepak L. Bhatt, M.D., M.P.H., F.A.C.C., F.A.H.A., has joined the Company's Medical Advisory Board. Regado will benefit from Dr. Bhatt's expertise in cardiovascular intervention and years of experience leading international cardiovascular clinical trials, as the Company actively enrolls patients in its Phase 3 REGULATE-PCI study and positions REG-1 as a potential standard of care for anticoagulant use in percutaneous coronary intervention procedures.

  • 11 December 2013

    Venter Pharma and NovaMedica Sign Agreement to Commercialize New Lactose Intolerance Test in Russia

    Venter Pharma and NovaMedica Sign Agreement to Commercialize New Lactose Intolerance Test in Russia

    NovaMedica LLC, a Russian pharmaceutical  company, and Venter Pharma SL, a Spanish company, developing innovative diagnostic systems, have signed a partnership agreement that grants NovaMedica exclusive rights to commercialize a new technology for the diagnosis of lactose intolerance,  LacTEST®, in Russia and the Community of Independent States (CIS).

  • 09 December 2013

    Regado Biosciences strengthens executive leadership

    Regado Biosciences strengthens executive leadership

    Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced the appointment of Michael A. Metzger to its executive management team, where he will serve as President and Chief Operating Officer.  In this role, he will oversee corporate and business development strategy and planning, as well as other key business functions of the company.  Mr. Metzger was previously Executive Vice President and Chief Operating Officer at Mersana Therapeutics.